Polysaccharide-protein conjugates
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsShousun C. Szu, Rachel Schneerson, John B. Robbins
Life of this patent
Estimating the term…
Abstract
Vi capsular polysaccharides conjugated to toxin-dependent proteins can be used to enhance antibody response and to convert T-dependent properties to the Vi capsular polysaccharide. A heterobifunctional crosslinking agent can be used to bind thiol derivatives of the Vi capsular polysaccharides to the proteins, such as diphtheria, tetanus toxoids, cholera toxin and Haemophilus influenzae.
Claims18
A method for conjugating capsular polysaccharide having carboxyl groups to a protein comprising:
- (a) forming a thiol derivative of the carboxyl groups of the polysaccharide;
- and
- (b) binding said thiol derivative to a protein using a heterobifunctional crosslinking agent.
A composition for enhancing the antibody response of a host comprising a capsular polysaccharide having carboxyl groups conjugated through a thio derivative of said carboxyl groups to a protein in a physiologically acceptable carrier.
Dependencies are inferred from the claim text.